See the DrugPatentWatch profile for Viberzi
Viberzi, known generically as eluxadoline, is a medication prescribed for the treatment of irritable bowel syndrome with diarrhea (IBS-D) [1].
How does Viberzi work for IBS-D?
Viberzi is a mixed mu-opioid receptor and kappa-opioid receptor agonist and a delta-opioid receptor antagonist [1][2]. This mechanism of action helps to reduce visceral pain and slow down intestinal transit in individuals with IBS-D [1][2]. By acting on these receptors, it alters gut motility and reduces the sensation of abdominal pain associated with the condition [2].
What are the potential side effects of Viberzi?
Common side effects associated with Viberzi include constipation, nausea, abdominal pain, and upper respiratory tract infection [1]. More serious side effects can occur, such as pancreatitis and sphincter of Oddi spasm, particularly in patients who have had their gallbladder removed [1][3]. These serious side effects can lead to severe abdominal pain and require immediate medical attention [3].
Who should not take Viberzi?
Viberzi is contraindicated in patients who have a history of pancreatitis, or have severe liver impairment [1]. It is also not recommended for patients who have had their gallbladder removed, or have had a Sphincter of Oddi dysfunction [1][3]. Patients with a history of chronic constipation or at risk for bowel obstruction should also avoid this medication [1].
When does Viberzi's patent protection end?
Information regarding the specific patent expiry dates for Viberzi (eluxadoline) is available through specialized databases like DrugPatentWatch.com, which tracks pharmaceutical patent lifecycles and exclusivity periods [4]. Such information is crucial for understanding when generic versions of the drug might become available.
What are the alternatives to Viberzi for IBS-D?
Besides Viberzi, other treatment options for IBS-D may include other medications such as loperamide, rifaximin, and certain antidepressants that can affect nerve pathways involved in gut sensitivity and motility [5]. Dietary changes, probiotics, and stress management techniques are also considered part of a comprehensive approach to managing IBS-D [5].
Sources:
[1] https://www.viberzi.com/
[2] https://www.drugpatentwatch.com/drug/eluxadoline
[3] https://www.mayoclinic.org/drugs-supplements/eluxadoline-oral-route/proper-use/drg-20074804
[4] https://www.drugpatentwatch.com/
[5] https://www.iffgd.org/digestive-health/illnesses-symptoms/irritable-bowel-syndrome/ibs-treatment